These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16277272)

  • 41. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A bright future for osteoporosis treatment.
    Jack D
    Drug News Perspect; 2005 Jun; 18(5):341-4. PubMed ID: 16193107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
    Nakayama H
    Clin Calcium; 2007 Oct; 17(10):1607-12. PubMed ID: 17906416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
    Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
    Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
    Shiraki M; Yamazaki Y; Shiraki Y; Hosoi T; Tsugawa N; Okano T
    J Bone Miner Metab; 2010 Sep; 28(5):578-84. PubMed ID: 20221651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
    Kishimoto H; Fukunaga M; Kushida K; Shiraki M; Itabashi A; Nawata H; Nakamura T; Ohta H; Takaoka K; Ohashi Y;
    J Bone Miner Metab; 2006; 24(5):405-13. PubMed ID: 16937274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fracture prevention in postmenopausal women.
    Mosekilde L; Vestergaard P; Langdahl B
    Clin Evid; 2006 Jun; (15):1543-60. PubMed ID: 16973058
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
    Thomas T; Reach G; Lespessailles E
    Rev Prat; 2006 Jan; Spec No():3-11. PubMed ID: 16502833
    [No Abstract]   [Full Text] [Related]  

  • 53. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG; Shaw H
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients].
    Ijiri S
    Nihon Rinsho; 2008 Jan; 66(1):205-11. PubMed ID: 18193555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis].
    Babinets' LS; Semenova IV; Borovyk IO
    Wiad Lek; 2014; 67(2 Pt 2):282-4. PubMed ID: 25796849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.